Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)

European Journal of Cancer

Volumn 44, Issue 9, 2008, Pages 1210-1216

  Hildebrand, Jerzy ^a   Gorlia, Thierry ^b   Kros, Johan M ^c   Afra, Dénes ^d   Frenay, Marc ^e   Omuro, Antonio ^f   Stupp, Roger ^g   Lacombe, Denis ^b   Allgeier, Anouk ^b   van den Bent, Martin J ^c  

^a ERASME HOSPITAL   (Belgium)

^b EORTC DATA CENTER   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE OF NEUROSURGERY   (Hungary)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Adjuvant therapy; Anaplastic astrocytomas; Dibromodulcitol; High grade gliomas; Pathology review

Indexed keywords

CARMUSTINE; MITOLACTOL;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MITOLACTOL; TREATMENT FAILURE;

EID: 44449135504     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.12.005     Document Type: Article

References (19)

1. Glioma Meta-Analysis Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
2. Hildebrand J., Sahmoud T., Mignolet F., Brucher J.M., Afra D., and The EORTC Brain Tumor Group. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44 (1994) 1479-1483
3. Prados M.D., Seiferheld W., Sandler H.M., et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58 (2004) 1147-1152
4. Levin V.A., Hess K.R., Choucair A., et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9 3 (2003) 981-990
5. Jeney A., Kovalszky I., Raso E., Durand R.E., Furesz J., and Lapis K. The biological activity of cisplatin and dibromodulcitol in combination therapy. Br J Cancer 71 2 (1995) 317-321
6. Pulst S.M., and Deen D.F. Potentiation of BCNU-induced cytotoxicity and sister chromatid exchanges by dibromodulcitol in vitro. Anticancer Res 10 6 (1990) 1647-1650
7. Afra D., Kocsis B., Dobay J., and Eckhardt S. Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. J Neurosurg 59 1 (1983) 106-110
8. Csetenyi J., Afra D., Kerpel-Fronius S., Horvath I.P., Institoris L., and Eckhardt S. The distribution of [3H]-dibromodulcitol in the central nervous system of patients with brain tumour. Eur J Cancer Clin Oncol 19 10 (1983) 1389-1392
9. Zülch KJ. WHO: International histological classification of tumours no. 21. Histological typing of tumours of the central nervous system. Geneva, Switzerland; 1979.
10. Kleihues P., Burger P.C., and Scheithauer B.W. Histological typing of tumours of the central nervous system (1993), Springer-Verlag, Berlin, Heidelberg, New York
11. Kleihues P, Cavenee WK. World Health Classification of tumours. Pathology and genetics of tumours of the nervous system. Lyon, International Agency for the Research on Cancer; 2000.
12. Coons S.W., Johnson P.C., Scheithauer B.W., Yates A.J., and Pearl D.K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79 (1997) 1381-1391
13. Burger P.C. What is an oligodendroglioma?. Brain Pathol 12 2 (2002) 257-259
14. Kros J.M., Gorlia T., Kouwenhoven M.C., et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss and correlations with outcome. J Neuropath Exp Neur 66 6 (2007) 545-551
15. Scott C.B., Nelson J.S., Farnan N.C., et al. Central pathology review in clinical trials for patients with malignant glioma. Cancer 76 (1995) 307-313
16. Smith J.S., Perry A., Borell T.J., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol 18 (2000) 636-645
17. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
18. Cairncross J.G., Berkey B., Shaw E., et al. Phase III trial of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): an intergroup trial by the RTOG, NCCTG, SWOG, NCI CTG and ECOG. J Clin Oncol 24 (2006) 2707-2714
19. van den Bent M.J., Carpentier A.F., Brandes A.A., et al. Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol 24 (2006) 2715-2722